Notably, only one biological agent has received approval for use in both diseases: the anti‐IL4/IL13 dupilumab is effective at reducing exacerbation rates [11] and maintenance oral corticosteroid (mOCS) use [12] in severe asthma, and it also significantly reduces disease burden in atopic dermatitis [13]. Here, IL13 is linked to atopic eczema.